 The registry will enroll 2 groups of patients. One group will include patients who are currently taking lupus medicines along with intravenous BENLYSTA With BENLYSTA. The other group will include patients who are taking lupus medicines but do not take BENLYSTA Without BENLYSTA. For every 3 participants enrolled in the registry, 2 will be taking BENLYSTA and 1 will not. After enrollment, changes in lupus medications, including starting or stopping BENLYSTA, are at the discretion of the physician, and all patients will continue to be followed regardless of changes in their lupus medicines until study completion. Physicians will manage the patient in accordance with their medical judgment and standard of care. Data will be collected at enrollment and at 6 month intervals for 5 years. 